STREAM Program Delivers Actionable Genomic Insights for 59% of Pediatric Cancer Patients in Asia's First Nationwide WGS Initiative
核心洞察
The STREAM Program, Asia's first nationwide precision oncology initiative for pediatric solid tumors (搜索), has profiled 308 children using whole genome sequencing and delivered clinically actionable findings in 59% of cases.
Pediatric tumors showed unique characteristics including 14-fold lower mutational burden compared to adult cancers and typically only two driver events per patient, revealing pediatric-specific therapeutic vulnerabilities.
The program successfully integrated multi-omic profiling and ex-vivo drug screening into routine pediatric care, with 82% of patients having at least one somatic driver mutation across 400+ genes.
The STREAM Program (Strategic TREatment And Magic for pediatric cancers) has achieved a significant milestone in pediatric precision oncology, delivering clinically actionable genomic insights to 59% of the 308 children profiled to date. The landmark initiative, funded by the Lee Kun-hee Child Cancer and Rare Disease Project (搜索) and powered by Inocras (搜索)' whole genome sequencing platform, represents Asia's first nationwide, real-world precision oncology program for pediatric solid tumors (搜索).
Results from the program were presented at the American Association for Cancer Research (AACR) Special Conference on Advances in Pediatric Cancer (搜索) Research in Boston, demonstrating the successful integration of comprehensive genomic profiling into routine pediatric oncology care.
Comprehensive Genomic Profiling Reveals Unique Pediatric Tumor Biology
The STREAM Program identified 1,082 somatic driver mutations (搜索) across 308 patients, with 56% consisting of non-SNV events including 238 copy number variants (搜索) (CNVs) and 323 structural variants (搜索) (SVs). Notably, 82% of patients had at least one somatic driver, spanning more than 1,000 genomic events across 400+ genes.
The analysis revealed distinctive characteristics of pediatric tumors compared to adult cancers. Pediatric tumors exhibited a 14-fold lower mutational burden and typically contained only two driver events per patient, highlighting pediatric-specific therapeutic vulnerabilities that differ significantly from adult oncology.
"This national-scale program shows that genome-guided care for children with cancer is no longer a future concept – it is happening right now in clinics," said Jehee Suh, CEO of Inocras (搜索). "STREAM has already delivered clinically actionable findings in more than half of patients, driven in large part by structural and fusion variants, and is uncovering unique aspects of pediatric tumor biology such as low mutational burden and single pathway dependencies."
Clinical Implementation and Real-World Impact
Launched in Korea in 2023, STREAM integrates whole genome sequencing, transcriptome and methylome profiling, and ex-vivo drug screening into routine pediatric care. The program's multi-omic approach has proven effective in real-world clinical settings, with molecular profiling not only mirroring histology but also revealing new genomic clusters that more accurately predicted treatment response.
The 59% of patients who achieved clinically actionable results experienced direct benefits including diagnostic refinement, therapeutic guidance, or clinical trial eligibility. Additionally, 10% of patients carried pathogenic germline variants (搜索), supporting family counseling and early interventions.
Ex-vivo drug testing demonstrated strong concordance with genomic signatures, enabling genome-guided therapy recommendations in real-world tumor boards. These findings provide crucial support for designing future pediatric basket trials based on pathway dependencies rather than traditional tumor morphology.
Advancing Pediatric Precision Medicine
"This initiative represents a major step forward for pediatric cancer (搜索) care in Korea and around the world," said Dr. Ji Hoon Phi, Associate Professor, Division of Pediatric Neurosurgery of Seoul National University Children's Hospital (搜索) and head of the solid tumor division under the Child Cancer and Rare Disease Support Project. "By embedding multi-omic profiling and ex-vivo drug screening into pediatric oncology workflows, and by revealing novel molecular subgroups that transcend traditional histology, we are setting a new standard for how children with cancer are diagnosed and treated."
The program is on track to reach 500 patients in the near term as part of a broader 10-year initiative targeting 2,000 patients nationwide. This scale represents a transformative approach to pediatric cancer (搜索) care, demonstrating that comprehensive genomic profiling can be successfully implemented in routine clinical practice while delivering meaningful therapeutic insights.
The STREAM Program's success in delivering actionable genomic insights to the majority of pediatric cancer (搜索) patients marks a significant advancement in precision medicine for children, establishing a new paradigm for integrating comprehensive molecular profiling into standard pediatric oncology care.